Consumption of broccoli sprouts significantly lowers blood pressure, potentially due to properties of sulforaphane.
The research pulled from ten clinical trials studying human subjects' cardiometabolic health in relation to broccoli sprout supplementation. The literature used for this systematic review and meta-analysis was compiled from research found on Pubmed and Scopus up until June 2022, the range of studies spanned from 2004 to 2019. To create a valid comparison, seven of the clinical trials contained control groups.
Discussing the results, it was found that the intake of broccoli sprouts brought significant reductions in both systolic and diastolic blood pressures. In addition, minor changes in blood lipid biomarkers were also tracked when compared to their baseline levels. These results confirmed the vegetable's hypotensive properties and brought attention to the potential sulforaphane-dependent effects it holds, thus underlining broccoli sprouts' value in managing cardiometabolic diseases.
